<p>Mutations in <i>ERBB2</i> (ENST00000269571) grouped into four hotspots (top). Samples (n = 29) with a mutated member of ERBB receptor family are presented in columns (below). In addition to a hotspot mutation, some samples displayed simultaneously a non-hotspot mutation in the same gene, thus all mutations are not shown in the figure. Recep_L = Receptor L domain; Furin-like = Furin-like cysteine rich region; GF_recep = Growth factor receptor domain; Pkinase_Tyr = Protein tyrosine kinase.</p
The pressure exerted by drugs targeted to a protein in any therapy inevitably leads to the emergence...
<p>(<b>A</b>) SH2 recruitment potential of ErbB1 family members at different affinity thresholds. Th...
Acquired mutations on fulvestrant. A, Incidence of acquired alterations (n = 69 assessable patients)...
<p>(a, b) Mapping of the different ERBB3 functions to specific regions of the protein. Each function...
There are numerous reports of ERBB mutations in various cancer types. Majority of the identified can...
We assessed somatic alleles of six receptor tyrosine kinase genes mutated in lung adenocarcinoma for...
The structure model of ERBB2 (GenBank accession: NM_001289937) was generated using the online tool S...
In cancer genomics, frequent recurrence of mutations in independent tumor samples is a strong indica...
<p>(A) Mutations in the XPD/ERCC2 protein domains. The diagram shows the ERCC2 protein with the four...
<p>Epidermal growth factor receptor (EGFR) mutation spectrum among patients with EGFR-mutant lung ad...
<p>Genomic location of these mutations in the tyrosine kinase (TK) domain of EGFR (A) and ErbB2 (B)....
<div><p>The pressure exerted by drugs targeted to a protein in any therapy inevitably leads to the e...
We describe a novel ERBB1/EGFR somatic mutation (p. C329R; c.985 T > C) identified in a patient with...
The pressure exerted by drugs targeted to a protein in any therapy inevitably leads to the emergence...
Despite the ongoing ‘war on cancer’, cancer remains one of the major causes of human morbidity and m...
The pressure exerted by drugs targeted to a protein in any therapy inevitably leads to the emergence...
<p>(<b>A</b>) SH2 recruitment potential of ErbB1 family members at different affinity thresholds. Th...
Acquired mutations on fulvestrant. A, Incidence of acquired alterations (n = 69 assessable patients)...
<p>(a, b) Mapping of the different ERBB3 functions to specific regions of the protein. Each function...
There are numerous reports of ERBB mutations in various cancer types. Majority of the identified can...
We assessed somatic alleles of six receptor tyrosine kinase genes mutated in lung adenocarcinoma for...
The structure model of ERBB2 (GenBank accession: NM_001289937) was generated using the online tool S...
In cancer genomics, frequent recurrence of mutations in independent tumor samples is a strong indica...
<p>(A) Mutations in the XPD/ERCC2 protein domains. The diagram shows the ERCC2 protein with the four...
<p>Epidermal growth factor receptor (EGFR) mutation spectrum among patients with EGFR-mutant lung ad...
<p>Genomic location of these mutations in the tyrosine kinase (TK) domain of EGFR (A) and ErbB2 (B)....
<div><p>The pressure exerted by drugs targeted to a protein in any therapy inevitably leads to the e...
We describe a novel ERBB1/EGFR somatic mutation (p. C329R; c.985 T > C) identified in a patient with...
The pressure exerted by drugs targeted to a protein in any therapy inevitably leads to the emergence...
Despite the ongoing ‘war on cancer’, cancer remains one of the major causes of human morbidity and m...
The pressure exerted by drugs targeted to a protein in any therapy inevitably leads to the emergence...
<p>(<b>A</b>) SH2 recruitment potential of ErbB1 family members at different affinity thresholds. Th...
Acquired mutations on fulvestrant. A, Incidence of acquired alterations (n = 69 assessable patients)...